Clincosm LogoSign in Get a demo

Triple Negative Breast Cancer

Showing NaN - NaN of 44
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer Trial in New York, Fairfax, Spokane (XMT-1660)

Recruiting
  • Triple Negative Breast Cancer
  • +5 more
  • Orange, California
  • +6 more
Jan 23, 2023

Triple Negative Breast Cancer, PD-L1 Negative Trial in Puerto Rico, United States (Sacituzumab Govitecan-hziy, Paclitaxel,

Recruiting
  • Triple Negative Breast Cancer
  • PD-L1 Negative
  • Sacituzumab Govitecan-hziy
  • +4 more
  • Anchorage, Alaska
  • +231 more
Jan 17, 2023

Triple Negative Breast Cancer, PD-L1 Positive Trial in Puerto Rico, United States (Sacituzumab Govitecan-hziy, Pembrolizumab,

Recruiting
  • Triple Negative Breast Cancer
  • PD-L1 Positive
  • Sacituzumab Govitecan-hziy
  • +5 more
  • Anchorage, Alaska
  • +245 more
Jan 12, 2023

NSCLC, Gastric Carcinoma, Gastroesophageal Junction Carcinoma Trial in Worldwide (SEA-TGT, sasanlimab)

Recruiting
  • Non-small Cell Lung Cancer
  • +11 more
  • Birmingham, Alabama
  • +32 more
Jan 4, 2023

Melanoma, NSCLC, Bladder Cancer Trial in Worldwide (Autogene cevumeran, Atezolizumab)

Active, not recruiting
  • Melanoma
  • +7 more
  • Scottsdale, Arizona
  • +36 more
Dec 22, 2022

Triple Negative Breast Cancer Trial in Worldwide (Atezolizumab, Paclitaxel, Dose-dense Doxorubicin or dose-dense Epirubicin)

Active, not recruiting
  • Triple Negative Breast Cancer
  • Concord, California
  • +429 more
Dec 12, 2022

Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph

Recruiting
  • Triple Negative Breast Cancer
  • +2 more
  • Radiation Therapy Boost
  • +6 more
  • Washington, District of Columbia
  • +8 more
Dec 5, 2022

Triple Negative Breast Cancer Trial in New York (Merck 3475 Pembrolizumab, Intraoperative radiation therapy (IORT))

Recruiting
  • Triple Negative Breast Cancer
  • Merck 3475 Pembrolizumab
  • Intraoperative radiation therapy (IORT)
  • New York, New York
    Columbia University Irving Medical Center
Oct 10, 2022

Breast Cancer, Colorectal Cancer, Ovarian Cancer Trial in United States (ATRC-101, Pembrolizumab, Pegylated liposomal

Recruiting
  • Breast Cancer
  • +15 more
  • ATRC-101
  • +2 more
  • Phoenix, Arizona
  • +10 more
Sep 28, 2022

Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer Trial in United States (Paclitaxel, CB-839)

Completed
Has Results
  • Triple Negative Breast Cancer
  • TNBC - Triple-Negative Breast Cancer
  • Birmingham, Alabama
  • +24 more
Sep 19, 2022

Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Metastatic Breast Cancer Trial in United States (Stereotactic Body

Recruiting
  • Triple Negative Breast Cancer
  • +3 more
  • Stereotactic Body Radiotherapy/SBRT
  • Systemic Therapy/Standard of Care
  • Hartford, Connecticut
  • +11 more
Aug 24, 2022

Breast Cancer, Triple Negative Breast Cancer Trial in New York (Sodium (Na) Magnetic Resonance Imaging (MRI), Dynamic Contrast-

Terminated
Has Results
  • Breast Cancer
  • Triple Negative Breast Cancer
  • Sodium (Na) Magnetic Resonance Imaging (MRI)
  • Dynamic Contrast- Enhanced (DCE) MRI
  • New York, New York
    NYU Langone Health
Aug 1, 2022

Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer Trial in Worldwide (Pembrolizumab, Lenvatinib)

Active, not recruiting
  • Advanced Solid Tumors
  • +7 more
  • Duarte, California
  • +87 more
Aug 19, 2022

Ovarian Cancer, Ovarian Tumors, Ovarian Carcinoma Trial in United States (ELU001)

Recruiting
  • Ovarian Cancer
  • +68 more
  • Phoenix, Arizona
  • +8 more
Aug 18, 2022

Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma Trial in United Kingdom, United States

Terminated
  • Pancreatic Adenocarcinoma
  • +13 more
  • San Francisco, California
  • +7 more
Aug 17, 2022

Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer Trial in United States (navicixizumab+paclitaxel,

Recruiting
  • Colorectal Cancer
  • +3 more
  • navicixizumab+paclitaxel
  • +2 more
  • Hot Springs, Arkansas
  • +5 more
Aug 9, 2022

NSCLC, Renal Cell Cancer, Colorectal Cancer Trial in Australia, United States (CPI-006, CPI-006 + ciforadenant, CPI-006 +

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • +12 more
  • Tucson, Arizona
  • +26 more
Aug 1, 2022

TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer, NSCLC Trial in United States (Sterotactic Body

Active, not recruiting
  • TNBC - Triple-Negative Breast Cancer
  • +6 more
  • Sterotactic Body Radiotherapy/SBRT
  • Standard of care
  • Basking Ridge, New Jersey
  • +8 more
Jul 26, 2022

Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer Trial in United States (NKTR-262, bempegaldesleukin, nivolumab)

Terminated
  • Melanoma
  • +6 more
  • Scottsdale, Arizona
  • +13 more
Jun 24, 2022

Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer Trial in Worldwide (INCB106385, INCMGA00012)

Recruiting
  • Ovarian Cancer
  • +10 more
  • West Hollywood, California
  • +27 more
Jun 27, 2022

Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer Trial in Worldwide (Combination of NKTR-214 + nivolumab)

Completed
  • Melanoma
  • +6 more
  • Combination of NKTR-214 + nivolumab
  • La Jolla, California
  • +57 more
Jun 22, 2022

Breast Cancer, Early Stage, Triple Negative Breast Cancer Trial in United States (Enzalutamide, assessment)

Active, not recruiting
  • Breast Cancer
  • +2 more
  • Hartford, Connecticut
  • +11 more
Apr 26, 2022

Triple Negative Breast Cancer Trial in Worldwide (AL101)

Active, not recruiting
  • Triple Negative Breast Cancer
  • Gilbert, Arizona
  • +28 more
Mar 31, 2022

De-convoluting Interactions Between Genes, Cancer Environment,

Recruiting
  • Triple Negative Breast Cancer
  • Live Biobank
  • New York, New York
  • +1 more
Mar 26, 2022

Triple Negative Breast Cancer Trial in United States (Cisplatin, Paclitaxel)

Active, not recruiting
Has Results
  • Triple Negative Breast Cancer
  • Birmingham, Alabama
  • +19 more
Feb 14, 2022